乳腺癌动物模型的研究进展
Research Progress in Animal Models of Breast Cancer
DOI: 10.12677/acm.2026.1631207, PDF,   
作者: 李 姗:温州大学生命与环境科学学院,浙江 温州
关键词: 乳腺瘤动物模型化学诱导模型移植模型Breast Neoplasm Animal Models Chemically Induced Models Transplant Models
摘要: 乳腺癌作为全球女性群体中确诊率位居前列的癌症类型,其内部存在的诸多异质性为研究工作增添了挑战。乳腺癌研究在很大程度上依赖于多样化的模型系统,以了解疾病进展、开发新型诊断方法并评估新的治疗策略。动物模型一直是我们探索癌症病理、构建与人类癌症高度相似的体内微环境的重要工具。这些模型在癌症相关临床研究中不可或缺,精准识别与疾病预后紧密相关的生物标志物和遗传通路。化学诱导模型成本低且易于构建;移植模型能够可靠地模拟人类乳腺癌环境;基因工程小鼠模型有助于揭示所涉及的基因改变,并测试新型免疫疗法;本文概述了乳腺癌动物模型研究方法进展,旨在为从事乳腺癌研究、并需根据研究目的精心挑选最佳模型的研究人员提供坚实的支撑与参考。
Abstract: Breast cancer ranks among the top cancer types in terms of incidence among the global female population. The significant heterogeneity within breast cancer poses challenges to research endeavors. Breast cancer research heavily relies on diverse model systems to understand disease progression, develop novel diagnostic methods, and evaluate new therapeutic strategies. Animal models have consistently served as crucial tools for exploring cancer pathology and constructing in vivo microenvironments that closely resemble human cancers. These models are indispensable in cancer-related clinical research, enabling the precise identification of biomarkers and genetic pathways closely associated with disease prognosis. Chemically induced models are cost-effective and easy to establish; transplant models reliably simulate the human breast cancer environment; genetically engineered mouse models facilitate the revelation of involved genetic alterations and the testing of novel immunotherapies. This paper provides an overview of the research advancements in breast cancer animal models, aiming to offer robust support and reference for researchers engaged in breast cancer studies who need to carefully select the optimal model based on their research objectives.
文章引用:李姗. 乳腺癌动物模型的研究进展[J]. 临床医学进展, 2026, 16(3): 3964-3970. https://doi.org/10.12677/acm.2026.1631207

参考文献

[1] Hu, W., Xu, D. and Li, N. (2023) Research Status of Systemic Adjuvant Therapy for Early Breast Cancer. Cancer Control, 30, 1-12. [Google Scholar] [CrossRef] [PubMed]
[2] Larkin, L. (2023) Breast Cancer Genetics and Risk Assessment: An Overview for the Clinician. Climacteric, 26, 229-234. [Google Scholar] [CrossRef] [PubMed]
[3] Gordon, P.B. (2022) The Impact of Dense Breasts on the Stage of Breast Cancer at Diagnosis: A Review and Options for Supplemental Screening. Current Oncology, 29, 3595-3636. [Google Scholar] [CrossRef] [PubMed]
[4] Singhal, S.S., Garg, R., Mohanty, A., Garg, P., Ramisetty, S.K., Mirzapoiazova, T., et al. (2023) Recent Advancement in Breast Cancer Research: Insights from Model Organisms—Mouse Models to Zebrafish. Cancers, 15, Article 2961. [Google Scholar] [CrossRef] [PubMed]
[5] Jain, M. and Goel, A. (2024) Current Insights in Murine Models for Breast Cancer: Present, Past and Future. Current Pharmaceutical Design, 30, 2267-2275. [Google Scholar] [CrossRef] [PubMed]
[6] Bu, W. and Li, Y. (2025) Rat Models of Breast Cancer. In: Sørlie, T. and Clarke, R.B., Eds., A Guide to Breast Cancer Research, Springer, 123-148. [Google Scholar] [CrossRef] [PubMed]
[7] Silva, J., Oliveira, P.A., Duarte, J.A. and Faustino-ROCHA, A.I. (2024) Mammary Cancer Models: An Overview from the Past to the Future. In Vivo, 39, 1-16. [Google Scholar] [CrossRef] [PubMed]
[8] Nuckhir, M., Withey, D., Cabral, S., Harrison, H. and Clarke, R.B. (2024) State of the Art Modelling of the Breast Cancer Metastatic Microenvironment: Where Are We? Journal of Mammary Gland Biology and Neoplasia, 29, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
[9] Miller, J.L., Bartlett, A.P., Harman, R.M., Majhi, P.D., Jerry, D.J. and Van de Walle, G.R. (2022) Induced Mammary Cancer in Rat Models: Pathogenesis, Genetics, and Relevance to Female Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 27, 185-210. [Google Scholar] [CrossRef] [PubMed]
[10] Pedroza, D.A., Gao, Y., Zhang, X.H. and Rosen, J.M. (2024) Leveraging Preclinical Models of Metastatic Breast Cancer. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1879, Article ID: 189163. [Google Scholar] [CrossRef] [PubMed]
[11] Zhou, Y., Xia, J., Xu, S., She, T., Zhang, Y., Sun, Y., et al. (2023) Experimental Mouse Models for Translational Human Cancer Research. Frontiers in Immunology, 14, Article 1095388. [Google Scholar] [CrossRef] [PubMed]
[12] Ferreira, T., Azevedo, T., Silva, J., Faustino-Rocha, A.I. and Oliveira, P.A. (2023) Current Views on in Vivo Models for Breast Cancer Research and Related Drug Development. Expert Opinion on Drug Discovery, 19, 189-207. [Google Scholar] [CrossRef] [PubMed]
[13] Yadav, R., Mahajan, S., Singh, H., Mehra, N.K., Madan, J., Doijad, N., et al. (2024) Emerging in Vitro and in Vivo Models: Hope for the Better Understanding of Cancer Progression and Treatment. Advanced Biology, 8, e2300487. [Google Scholar] [CrossRef] [PubMed]
[14] Bu, W. and Li, Y. (2023) Advances in Immunocompetent Mouse and Rat Models. Cold Spring Harbor Perspectives in Medicine, 14, a041328. [Google Scholar] [CrossRef] [PubMed]
[15] Nicotra, R., Lutz, C., Messal, H.A. and Jonkers, J. (2024) Rat Models of Hormone Receptor-Positive Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 29, Article No. 12. [Google Scholar] [CrossRef] [PubMed]
[16] Hilakivi-Clarke, L., Jolejole, T.K., da Silva, J.L., de Oliveira Andrade, F., Dennison, G. and Mueller, S. (2025) Aromatics from Fossil Fuels and Breast Cancer. iScience, 28, Article ID: 112204. [Google Scholar] [CrossRef] [PubMed]
[17] Silva, J., Duarte, J.A. and Oliveira, P.A. (2023) Realistic Aspects behind the Application of the Rat Model of Chemically-Induced Mammary Cancer: Practical Guidelines to Obtain the Best Results. Veterinary World, 16, 1222-1230. [Google Scholar] [CrossRef] [PubMed]
[18] Miret, N.V., Pontillo, C.A., Buján, S., Chiappini, F.A. and Randi, A.S. (2023) Mechanisms of Breast Cancer Progression Induced by Environment-Polluting Aryl Hydrocarbon Receptor Agonists. Biochemical Pharmacology, 216, Article ID: 115773. [Google Scholar] [CrossRef] [PubMed]
[19] Abderrahman, B. and Jordan, V.C. (2022) Estrogen for the Treatment and Prevention of Breast Cancer: A Tale of 2 Karnofsky Lectures. The Cancer Journal, 28, 163-168. [Google Scholar] [CrossRef] [PubMed]
[20] Santen, R.J., Stuenkel, C.A. and Yue, W. (2022) Mechanistic Effects of Estrogens on Breast Cancer. The Cancer Journal, 28, 224-240. [Google Scholar] [CrossRef] [PubMed]
[21] Dreyfuss, A.D., Velalopoulou, A., Avgousti, H., Bell, B.I. and Verginadis, I.I. (2022) Preclinical Models of Radiation-Induced Cardiac Toxicity: Potential Mechanisms and Biomarkers. Frontiers in Oncology, 12, Article 920867. [Google Scholar] [CrossRef] [PubMed]
[22] Hochman, J. and Braitbard, O. (2022) Life after Cleavage: The Story of a β-Retroviral (MMTV) Signal Peptide—From Murine Lymphoma to Human Breast Cancer. Viruses, 14, Article 2435. [Google Scholar] [CrossRef] [PubMed]
[23] Witt, B.L. and Tollefsbol, T.O. (2023) Molecular, Cellular, and Technical Aspects of Breast Cancer Cell Lines as a Foundational Tool in Cancer Research. Life, 13, Article 2311. [Google Scholar] [CrossRef] [PubMed]
[24] Das, S., Sahoo, S., Pattanaik, S., Prusty, R.K., Barik, B., Satapathy, B.S., et al. (2025) Advancing Breast Cancer Research: A Comprehensive Review of in Vitro and in Vivo Experimental Models. Medical Oncology, 42, Article No. 316. [Google Scholar] [CrossRef] [PubMed]
[25] Sharma, M.P., Shukla, S. and Misra, G. (2024) Recent Advances in Breast Cancer Cell Line Research. International Journal of Cancer, 154, 1683-1693. [Google Scholar] [CrossRef] [PubMed]
[26] Khairani, A.F., Harmonia, S., Chou, Y., Alfarafisa, N. and Ramadhanti, J. (2025) Optimizing Xenograft Models for Breast Cancer: A Comparative Analysis of Cell-Derived and Patient-Derived Implantation Techniques in Pre-Clinical Research. Breast Cancer: Targets and Therapy, 17, 1-10. [Google Scholar] [CrossRef] [PubMed]
[27] Souto, E.P., Dobrolecki, L.E., Villanueva, H., Sikora, A.G. and Lewis, M.T. (2022) In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts. Journal of Mammary Gland Biology and Neoplasia, 27, 211-230. [Google Scholar] [CrossRef] [PubMed]
[28] Jin, J., Yoshimura, K., Sewastjanow-Silva, M., Song, S. and Ajani, J.A. (2023) Challenges and Prospects of Patient-Derived Xenografts for Cancer Research. Cancers, 15, Article 4352. [Google Scholar] [CrossRef] [PubMed]
[29] Lewis, M.T. and Caldas, C. (2023) The Power and Promise of Patient-Derived Xenografts of Human Breast Cancer. Cold Spring Harbor Perspectives in Medicine, 14, a041329. [Google Scholar] [CrossRef] [PubMed]
[30] Blanchard, Z., Brown, E.A., Ghazaryan, A. and Welm, A.L. (2024) PDX Models for Functional Precision Oncology and Discovery Science. Nature Reviews Cancer, 25, 153-166. [Google Scholar] [CrossRef] [PubMed]
[31] Janitri, V., ArulJothi, K.N., Ravi Mythili, V.M., Singh, S.K., Prasher, P., Gupta, G., et al. (2024) The Roles of Patient‐derived Xenograft Models and Artificial Intelligence toward Precision Medicine. MedComm, 5, e745. [Google Scholar] [CrossRef] [PubMed]
[32] Yuan, Y., Gao, H., Li, Y. and Jiao, X. (2025) The Latest Progress of Personalized Drug Screening and Therapy Research for Common Clinical Tumors through the PDX Model Platform. Journal of Pharmaceutical Analysis, 15, Article ID: 101225. [Google Scholar] [CrossRef
[33] Higuchi, T., Yamamoto, N., Hayashi, K., Miwa, S., Igarashi, K., Tsuchiya, H., et al. (2023) High Clinical Concordance of Drug Resistance in Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: First Step to Validated Precise Individualized Cancer Chemotherapy. Anticancer Research, 43, 4277-4284. [Google Scholar] [CrossRef] [PubMed]
[34] Biswas, K., Mohammed, A., Sharan, S.K. and Shoemaker, R.H. (2023) Genetically Engineered Mouse Models for Hereditary Cancer Syndromes. Cancer Science, 114, 1800-1815. [Google Scholar] [CrossRef] [PubMed]
[35] Shanker, E.M. and Beck, A.P. (2023) If You Give a Mouse a Mutation: Comparing the Therapeutic Utility of Renowned Mouse Models of Human Cancers. Journal of Comparative Pathology, 203, 26-30. [Google Scholar] [CrossRef] [PubMed]
[36] Brauer, J., Tumani, M., Frey, N. and Lehmann, L.H. (2024) The Cardio-Oncologic Burden of Breast Cancer: Molecular Mechanisms and Importance of Preclinical Models. Basic Research in Cardiology, 120, 91-112. [Google Scholar] [CrossRef] [PubMed]
[37] Kaur, R., Sharma, A. and Wijekoon, N. (2025) Breast Cancer Preclinical Models: A Vital Resource for Comprehending Disease Mechanisms and Therapeutic Development. EXCLI Journal, 24, 267-285.
[38] Ciringione, A. and Rizzi, F. (2025) Facing the Challenge to Mimic Breast Cancer Heterogeneity: Established and Emerging Experimental Preclinical Models Integrated with Omics Technologies. International Journal of Molecular Sciences, 26, Article 4572. [Google Scholar] [CrossRef] [PubMed]
[39] Chowaniec, H., Ślubowska, A., Mroczek, M., Borowczyk, M., Braszka, M., Dworacki, G., et al. (2024) New Hopes for the Breast Cancer Treatment: Perspectives on the Oncolytic Virus Therapy. Frontiers in Immunology, 15, Article 1375433. [Google Scholar] [CrossRef] [PubMed]
[40] Peehl, D.M., Badea, C.T., Chenevert, T.L., Daldrup-Link, H.E., Ding, L., Dobrolecki, L.E., et al. (2023) Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials. Tomography, 9, 657-680. [Google Scholar] [CrossRef] [PubMed]
[41] Criscitiello, C., Guerini-Rocco, E., Viale, G., Fumagalli, C., Sajjadi, E., Venetis, K., et al. (2022) Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. Anti-Cancer Agents in Medicinal Chemistry, 22, 787-800. [Google Scholar] [CrossRef] [PubMed]
[42] Obeagu, E. (2025) N2 Neutrophils and Tumor Progression in Breast Cancer: Molecular Pathways and Implications. Breast Cancer: Targets and Therapy, 17, 639-651. [Google Scholar] [CrossRef] [PubMed]
[43] Tang, R. and Liu, X. (2024) Modeling Development of Breast Cancer: From Tumor Microenvironment to Preclinical Applications. Frontiers in Pharmacology, 15, Article 1466017. [Google Scholar] [CrossRef] [PubMed]